Respiratory Syncytial Virus Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV

The Respiratory Syncytial Virus Market Forecast report offers an in-depth understanding of the Respiratory Syncytial Virus, historical and forecasted epidemiology as well as the Respiratory Syncytial Virus market trends in the 7MM.
DelveInsight's "Respiratory Syncytial Virus Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Respiratory Syncytial Virus, historical and forecasted epidemiology as well as the Respiratory Syncytial Virus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Respiratory Syncytial Virus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Respiratory Syncytial Virus Market Forecast [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Respiratory Syncytial Virus Market Report:

*
The Respiratory Syncytial Virus market size was valued approximately USD 1200 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In February 2023, Becton, Dickinson, and Company received Emergency Use Authorization (EUA) from the Food and Drugs Administration (FDA) for its product BD MAX Molecular Diagnostic System combo test for SARS-CoV-2, influenza A + B and the respiratory syncytial virus.

*
In January 2023, Sonora Quest Laboratories launched qualitative, multi-target, molecular diagnostics testing that uses a patient sample to aid in detecting COVID-19, respiratory syncytial virus (RSV), and influenza.

*
As of 2022, the collective number of incident cases attributed to Respiratory Syncytial Virus (RSV) amounted to approximately 8,495,000 cases across the seven major markets (7MM). Projections suggest an anticipated rise in these cases by the year 2032.

*
In 2022, within the EU4 nations, Germany reported the highest count of incident cases related to Respiratory Syncytial Virus (RSV), reaching approximately 533,000 cases. This figure accounted for approximately 6% of the total cases documented across the seven major markets (7MM).

*
In 2022, Japan recorded an estimated total of around 983,000 incident cases linked to Respiratory Syncytial Virus (RSV), with forecasts indicating a potential increase in these cases by the year 2032.

*
In 2022, concerning the severity of Respiratory Syncytial Virus (RSV) infections among adults in the US, approximately 70% accounted for mild cases, 27% for moderate cases, and 3% for severe cases, collectively forming the total incident cases of RSV.

*
As per Zhang et al. 2022, among children under 5 years old, the incidence of Respiratory Syncytial Virus (RSV) between 2014 and 2018 was recorded at 17.3% (3449 out of 19,898 cases). Of those testing positive for RSV, 89.1% were hospitalized. Notably, a considerable proportion of RSV-infected individuals belonged to the age group under 6 months.

*
Key Respiratory Syncytial Virus Companies: GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, and others

*
Key Respiratory Syncytial Virus Therapies: RSVpreF3 Vaccine, MVA-BN RSV Vaccine, Ad26.RSV.pre F Vaccine, mRNA-1345 Vaccine, Nirsevimab (MEDI-8897), Sisunatovir, RSVpreF (PF-06928316), VAC 18193 (Ad26.RSV.preF), and others

*
Currently, the FDA has approved only two antiviral drugs for Respiratory Syncytial Virus (RSV)-related serious respiratory tract infections: aerosolized ribavirin used for treatment and palivizumab (SYNAGIS) for preventive prophylaxis. Ongoing research is focused on various types of RSV vaccines tailored for specific demographics, including pregnant women, infants, and the elderly.

*
The Respiratory Syncytial Virus market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Respiratory Syncytial Virus pipeline products will significantly revolutionize the Respiratory Syncytial Virus market dynamics.

Respiratory Syncytial Virus Overview

Respiratory Syncytial Virus (RSV) is a highly contagious virus that affects the respiratory system, primarily targeting the lungs and breathing passages. It commonly causes infections in the nose, throat, windpipe, and lungs. RSV is a significant cause of respiratory illness in infants and young children, often leading to mild cold-like symptoms such as coughing, sneezing, runny nose, fever, and sometimes wheezing. In older children and adults, RSV infections usually cause mild cold symptoms, but it can result in more severe respiratory problems in individuals with weakened immune systems or underlying health conditions.

Get a Free sample for the Respiratory Syncytial Virus Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market [https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Respiratory Syncytial Virus Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Respiratory Syncytial Virus Epidemiology Segmentation:

The Respiratory Syncytial Virus market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Respiratory Syncytial Virus

*
Prevalent Cases of Respiratory Syncytial Virus by severity

*
Gender-specific Prevalence of Respiratory Syncytial Virus

*
Diagnosed Cases of Episodic and Chronic Respiratory Syncytial Virus

Download the report to understand which factors are driving Respiratory Syncytial Virus epidemiology trends @ Respiratory Syncytial Virus Epidemiology Forecast [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Respiratory Syncytial Virus Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Respiratory Syncytial Virus market or expected to get launched during the study period. The analysis covers Respiratory Syncytial Virus market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Respiratory Syncytial Virus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Respiratory Syncytial Virus Therapies and Key Companies

*
RSVpreF3 Vaccine: GlaxoSmithKline

*
MVA-BN RSV Vaccine: Bavarian Nordic

*
Ad26.RSV.pre F Vaccine: Janssen

*
mRNA-1345 Vaccine: Moderna

*
Nirsevimab (MEDI-8897): MedImmune

*
Sisunatovir: ReViral

*
RSVpreF (PF-06928316): Pfizer

*
VAC 18193 (Ad26.RSV.preF): Janssen

Discover more about therapies set to grab major Respiratory Syncytial Virus market share @ Respiratory Syncytial Virus Treatment Landscape [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Respiratory Syncytial Virus Market Drivers

*
The successful trials of upcoming vaccines namely, RSVPref3, mRNA1345, and RSVPref have displayed the opportunity to change the treatment pattern mainly in the high risk patients i.e. elderly, infants and pregnant women. Further, the approval of these vaccines will proliferate the growth of the overall RSV market.

*
RSV infection can now be identified quickly due to advances in molecular diagnostics. A new taxonomic nomenclature for RSV was recently accepted, while diagnostic and omics approaches have revealed novel modalities for early detection of RSV infections and better knowledge of disease pathogenesis

Respiratory Syncytial Virus Market Barriers

*
RSV highlights the urgent need to develop more cost-effective antiviral preventive strategies, in order to decrease the burden of RSV infections requiring hospitalizations.

*
Data gaps in the disease burden need to be addressed to understand the epidemiology. Understanding these variances will be critical to establishing cost-effective interventions.

*
Combining RSV shots with other vaccines like influenza and COVID19 has the potential to offer a comprehensive and more efficient defense against various respiratory viruses.

Scope of the Respiratory Syncytial Virus Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Respiratory Syncytial Virus Companies: GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, and others

*
Key Respiratory Syncytial Virus Therapies: RSVpreF3 Vaccine, MVA-BN RSV Vaccine, Ad26.RSV.pre F Vaccine, mRNA-1345 Vaccine, Nirsevimab (MEDI-8897), Sisunatovir, RSVpreF (PF-06928316), VAC 18193 (Ad26.RSV.preF), and others

*
Respiratory Syncytial Virus Therapeutic Assessment: Respiratory Syncytial Virus current marketed and Respiratory Syncytial Virus emerging therapies

*
Respiratory Syncytial Virus Market Dynamics: Respiratory Syncytial Virus market drivers and Respiratory Syncytial Virus market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Respiratory Syncytial Virus Unmet Needs, KOL's views, Analyst's views, Respiratory Syncytial Virus Market Access and Reimbursement

To know more about Respiratory Syncytial Virus companies working in the treatment market, visit @ Respiratory Syncytial Virus Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Respiratory Syncytial Virus Market Report Introduction

2. Executive Summary for Respiratory Syncytial Virus

3. SWOT analysis of Respiratory Syncytial Virus

4. Respiratory Syncytial Virus Patient Share (%) Overview at a Glance

5. Respiratory Syncytial Virus Market Overview at a Glance

6. Respiratory Syncytial Virus Disease Background and Overview

7. Respiratory Syncytial Virus Epidemiology and Patient Population

8. Country-Specific Patient Population of Respiratory Syncytial Virus

9. Respiratory Syncytial Virus Current Treatment and Medical Practices

10. Respiratory Syncytial Virus Unmet Needs

11. Respiratory Syncytial Virus Emerging Therapies

12. Respiratory Syncytial Virus Market Outlook

13. Country-Wise Respiratory Syncytial Virus Market Analysis (2019-2032)

14. Respiratory Syncytial Virus Market Access and Reimbursement of Therapies

15. Respiratory Syncytial Virus Market Drivers

16. Respiratory Syncytial Virus Market Barriers

17. Respiratory Syncytial Virus Appendix

18. Respiratory Syncytial Virus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=respiratory-syncytial-virus-market-to-exhibit-rapid-growth-rate-during-the-forecast-period-20232032-investigates-delveinsight-glaxosmithkline-medimmune-reviral-pfizer-sanofi-biocomo-imv]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.